Investment in Equity Securities	3 Months Ended
Mar. 31, 2024
Equity Method Investments and Joint Ventures [Abstract]
Investment in Equity Securities	NOTE 4: INVESTMENT IN EQUITY SECURITIES The Company holds an investment in Dynamic Cell Therapies, Inc. (DCT), a U.S. private company that is in the pre-clinical stage of developing novel Chimeric Antigen Receptor (CAR) T-cell therapies based on technology licensed from a leading U.S. cancer treatment and research institution. The Company determined that DCT is a VIE however, the Company does not consolidate DCT because it does not have the power to direct economically significant activities. The Company has no obligation to provide any future funding to DCT and its maximum exposure to loss is its investment value, which is recorded in the Condensed Consolidated Balance Sheets as an Investment in equity securities. No impairment was recorded during the quarters ended March 31, 2024 and 2023, as a result of the Company's qualitative impairment analysis.

Investment in Equity Securities

3 Months Ended

Mar. 31, 2024

Equity Method Investments and Joint Ventures [Abstract]

NOTE 4: INVESTMENT IN EQUITY SECURITIES

The Company holds an investment in Dynamic Cell Therapies, Inc. (DCT), a U.S. private company that is in the pre-clinical stage of developing novel Chimeric Antigen Receptor (CAR) T-cell therapies based on technology licensed from a leading U.S. cancer treatment and research institution. The Company determined that DCT is a VIE however, the Company does not consolidate DCT because it does not have the power to direct economically significant activities. The Company has no obligation to provide any future funding to DCT and its maximum exposure to loss is its investment value, which is recorded in the Condensed Consolidated Balance Sheets as an Investment in equity securities.

No impairment was recorded during the quarters ended March 31, 2024 and 2023, as a result of the Company's qualitative impairment analysis.